1 t least 2 of the first 3 attacks switched to zolmitriptan, 2.5 mg, to treat the remaining 3 attacks;

2  hours in each attack escalated treatment to zolmitriptan, 2.5 mg.

3 rade III and IV treated up to 6 attacks with zolmitriptan, 2.5 mg; (2) step care across attacks (n =

4  telcagepant 150 mg (n=333) or 300 mg (354), zolmitriptan (345), or placebo (348).

5           Efficacy of telcagepant 300 mg and zolmitriptan 5 mg were much the same, and both were more

6 g, 37% taking telcagepant 300 mg, 51% taking zolmitriptan 5 mg, and 32% taking placebo.

7 migraine with efficacy comparable to that of zolmitriptan 5 mg, but with fewer associated adverse eff

8 th either oral telcagepant 150 mg or 300 mg, zolmitriptan 5 mg, or placebo.

9 ne (9/10 cells), sumatriptan (2/3 cells) and zolmitriptan (9/15 cells) but not by saline (3/10 cells)

10 ta for sumatriptan succinate nasal spray and zolmitriptan, eletriptan hydrobromide, almotriptan malat

11 n and eletriptan, and a nasal formulation of zolmitriptan have been recently developed.

12                                              Zolmitriptan nasal spray has a rapid onset of action and